Blood clotting substrate and medical device

• US 8,969,648 B2
• Filed: 04/06/2012
• Issued: 03/03/2015
• Est. Priority Date: 04/06/2012
• Status: Active Grant

• Current Assignee: Agency For Science Technology and Research (Government of Singapore), Depuy Synthes Products Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Luong-Van, Emma Kim, Rodriguez, Isabel, Low, Hong Yee, Ho, Audrey Yoke Yee, Natarajan, Sriram, Elmouelhi, Noha, Cooper, Kevin, Vyakarnam, Murty, Lim, Chee Tiong
• Primary Examiner(s): Lewis, Kim M
• Application Number:
  US13/441,539
• Publication Number:
  US 20130267880A1
• Time in Patent Office: 1,061 Days
• Field of Search: 602 41- 43, 602 47- 59, 428/99, 428/141, 428/156, 424/443
• US Class Current: 602/43
• CPC Class Codes: A61F 13/00063 comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic drug delivery dressings A61K9/70; chemical aspect of the additives A61L15/00
• CPC Class Codes: A61F 13/01017 synthetic, e.g. polymer based
• CPC Class Codes: A61F 2013/00472 with chemical means
• CPC Class Codes: B29C 59/14 by plasma treatment plasma tubes per se H01J
• CPC Class Codes: B29K 2023/12 PP, i.e. polypropylene

Abstract

A blood clotting substrate and device which has a plurality of oxygen plasma-treated polypropylene pillars extending from the surface of a polypropylene film.

Claims

1. A method of promoting blood clotting, comprising contacting blood with a blood clotting substrate comprising a plurality of oxygen plasma-treated polypropylene pillars extending from a surface of a oxygen plasma-treated polypropylene film, wherein the film and pillars demonstrate a normalized clotting time of 0.2, compared to an untreated film clot time of 0.9 when contacted with blood.

2. A method of promoting blood clotting, comprising contacting blood with a blood clotting medical device, comprising an oxygen plasma-treated polypropylene film having a plurality of oxygen plasma-treated polypropylene pillars extending from a surface thereof, wherein the oxygen plasma-treated polypropylene film and pillars demonstrate a normalized clotting time of 0.2, compared to an untreated film clot time of 0.9 when contacted with blood.

3. A method of forming a blood clotting substrate, comprising:

a) providing a mold dissolvable by a specific solvent including indentations;

b) providing a polypropylene film to the mold under conditions sufficient to permit filling the indentations of the mold by the polypropylene;

c) treating the mold and polypropylene of step b) to an extent sufficient to substantially solidify the polypropylene;

d) exposing the mold and polypropylene to the specific solvent selected to dissolve the mold but not the polypropylene under mold-dissolving conditions to provide a pillared substrate; and

e) oxygen plasma-treating the pillared substrate.

4. A blood clotting substrate, comprising a plurality of polypropylene pillars extending from a surface of a polypropylene film, wherein the polypropylene pillars and polypropylene film have been oxygen plasma-treated and demonstrate a normalized clotting time of 0.2, compared to an untreated film clot time of 0.9 when contacted with blood.

5. The blood clotting substrate of claim 4, wherein the pillars are of a diameter from about 0.8 μ

m to about 3 μ

m and have aspect ratios from about 0.5 to about 40.

6. The blood clotting substrate of claim 5, wherein the pillars have a diameter of about 1 μ

m and a height of about 20 μ

m.

7. The blood clotting substrate of claim 4, which has a static water contact angle of less than about 15°

.

8. The blood clotting substrate of claim 4, wherein the polypropylene film and pillars have a higher oxygen content on surfaces thereof than non-oxygen plasma treated polypropylene film and pillars.

9. The blood clotting substrate of claim 4, wherein the polypropylene film and pillars have an oxygen content of about 21%.

10. A blood clotting medical device, comprising an oxygen plasma-treated polypropylene film having a plurality of oxygen plasma-treated polypropylene pillars extending from a surface thereof, wherein the oxygen plasma-treated polypropylene film and pillars demonstrate a clotting time of 0.2, normalized to an untreated film clot time of 0.9 when contacted with blood.

11. The blood clotting medical device of claim 10, wherein the pillars are of a diameter from about 0.8 μ

m to about 3 μ

m and have aspect ratios from about 0.5 to about 40.

12. The blood clotting medical device of claim 11, wherein the pillars have a diameter of about 1 μ

m and a height of about 20 μ

m.

13. The blood clotting medical device of claim 10, which has a static water contact angle of less than about 15°

.

14. The blood clotting medical device of claim 10, wherein the polypropylene film and pillars have a higher oxygen content on surfaces thereof than non-oxygen plasma treated polypropylene film and pillars.

15. The blood clotting medical device of claim 10, wherein the polypropylene film and pillars have an oxygen content of about 21%.